Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Summary

This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.

Timeline

Start

2021-07-06

Primary completion

2024-12-31

Completion

2025-03-31

Publications

• Song N, Teng Y, Shi J, Teng Z, Jin B, Qu J, Zhang L, Yu P, Zhao L, Wang J, Li A, Tong L, Jiang S, Liu Y, Yin L, Jiang X, Xu T, Cui J, Qu X, Liu Y. A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study. Front Immunol. 2024 Nov 29;15:1481326. doi: 10.3389/fimmu.2024.1481326. eCollection 2024.

Drugs

Indications